New Mexico: compound legality at a glance

Instrument

16.19.20.65 NMAC (Board of Pharmacy, Schedule I), hallucinogenic substances

Source

https://www.srca.nm.gov/parts/title16/16.019.0020.html

Retrieved

2026-10-08

Fingerprint

d080906b38ee8437

16.19.20.65 SCHEDULE I: A. Section 30-31-6 NMSA 1978, schedule I shall consist of the following drugs and other substances, by whatever name, common or usual name, chemical name or brand name designated, listed in this section; OPIOIDS , unless specifically exempt or unless listed in another schedule, any of the following opioids, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. (1) Acetylmethadol; (2) Allylprodine ; (3) Alphacetylmethadol ; (4) Alphameprodine; (5) Alphamethadol ; (6) Alpha-methyl fentanyl; (7) Benzethidine ; (8) Betacetylmethadol; (9) Betameprodine ; (10) Betamethadol ; (11) Betaprodine ; (12) Clonitazene ; (13) Desmethyltramadol ; (14) Dextromoramide ; (15) Diampromide ; (16) Diethylthiambutene ; (17) Dimethylthiambutene ; (18) Difenoxin ; (19) Dimenoxadol ; (20) Dimepheptanol ; (21) Dimethylthiambutene ; (22) Dioxaphetyl Butyrate; (23) Dipipanone; (24) Ethylmethylthiambutene; (25) Etonitazene; (26) Etoxeridine; (27) Furethidine; (28) Hydroxypethidine ; (29) Isotonitazene ; (30) Ketobemidone; (31) Levomoramide; (32) Levophenacylmorphan; (33) Morpheridine; (34) Noracymethadol; (35) Norlevorphanol ; (36) Normethadone; (37) Norpipanone; (38) Phenadoxone; (39) Phenampromide; (40) Phenomorphan; (41) Phenoperidine; (42) Piritramide; (43) Proheptazine ; (44) Properidine ; (45) Propiram ; (46) Racemoramide; (47) Tilidine ; (48) Trimeperidine (49) U-48800; (2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide, monohydrochloride; (50) U-49900; (trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide; (51) Beta-Hydroxy-3-Methylfentanyl; (52) 3-Methylthiofentanyl; (53) Acetyl -Alpha- Methyl fentanyl ; (54) Alpha- Methylthiofentanyl ; (55) Beta- hydroxfentanyl ; (56) Para-Fluoro fentanyl ; (57) Thiofentanyl ; (58) Acetyl fentanyl ; (59) Butyryl fentanyl ; (60) Betahydroxythiofentanyl ; (61) Furanyl fentanyl ; (62) AH-7921; ( 3,4-dichloro-N-[(1- dimethylamino) cyclohexylmethyl ] benzamide ); (63) U47700; (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide); (64) MT-45; (1-(4- Nitrophenylethyl)piperidylidene -2-(4-chlorophenyl)sulfonamide); (65) W-15; (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide); (66) W-18; (1-(4- Nitrophenylethyl)piperidylidene -2-(4-chlorophenyl)sulfonamide); (67) U-50488; (2-(3,4-dichlorophenyl)-N- methyl -N-[(1R,2R)-2-pyrrolidin-1- ylcyclohexyl ] acetamide ); (68) U50488H; (( -)( trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny) cyclo - hexyl]benzeneacetamide). (69) Fentanyl-related substances, their isomers, esters, ethers, salts, and salts of isomers, esters and ethers. Fentanyl-related substance means any substance, unless specifically exempted or unless listed in another schedule, that is structurally related to fentanyl by one or more of the following modifications: (a) replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle; (b) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups; (c) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups; (d) replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or (e) replacement of the N-propionyl group by another acyl group; or (f) any combination of the above substances include, but are not limited to, the following substances: (reserved) (70) Acryl Fentanyl; (71) 4F-butyrfentanyl; (72) 4-methoxybutyrfentanyl; (73) Fluorobutyrfentanyl ; (74) Fluorofentanyl ; (75) FIBF; (Para Fluoro Isobutyryl Fentanyl); (76) Cyclopropyl fentanyl; (77) Thiofuranyl fentanyl (Thiophene fentanyl); (78) 3-methylfentanyl (N-3-methyl-1-(2-phenyl-ethyl)-4-Piperidyl)-N- phenylpropanamide , its optical and geometric isomers, salts and salts of isomers; (79) crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide ); (80) valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylpentanamide ); (81) N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide (2′-fluoro ortho- fluorofentanyl ; 2′-fluoro 2-fluorofentanyl); (82) N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide (4′-methyl acetyl fentanyl); (83) beta-phenyl fentanyl or N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide (β′-phenyl fentanyl; beta′-Phenyl fentanyl; 3-phenylpropanoyl fentanyl); (84) beta-methyl fentanyl or N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide (β-methyl fentanyl); (85) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (ortho- fluorobutyryl fentanyl; 2-fluorobutyryl fentanyl); (86) (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl acetylfentanyl ; 2-methyl acetylfentanyl ); (87) 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl methoxyacetylfentanyl ; 2-methyl methoxyacetyl fentanyl); (88) N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (para- methylfentanyl ; 4-methylfentanyl); (89) N-(1-phenethylpiperidin-4-yl)-N- phenylbenzamide (phenyl fentanyl; benzoyl fentanyl); (90) N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide ( thiofuranyl fentanyl; 2-thiofuranyl fentanyl; thiophene fentanyl); (91) Ethyl (1-phenethylpiperidin-4- yl )(phenyl)carbamate (fentanyl carbamate); (92) N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)acrylamide (ortho- fluoroacryl fentanyl); (93) N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl) isobutyramide (ortho- fluoroisobutyryl fentanyl); (94) N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2- carboxamide (para-fluoro furanyl fentanyl); (95) Cyclopentyl fentanyl; (96) Isobutyryl fentanyl; (97) Para -chloroisobutyryl fentanyl; (98) Para -methoxybutyryl fentanyl ; (99) Para -fluorobutyryl fentanyl ; (100) Ocfentanil ; (101) Ortho- Fluorofentanyl ; (102) Tetrahydrofuranyl Fentanyl ; (103) Methoxyacetyl Fentanyl ; (104) 4-Fluoroisobutyryl Fentanyl ; (105) Para- Fluorofentany;l (106) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1Hbenzimidazol-1-yl)- N,N -diethylethan-1- amine); (107) Etodesnitazene ; etazene (2-(2-(4-ethoxybenzyl)-1Hbenzimidazol-1-yl)- N,N -diethylethan-1- amine); (108) Metonitazene (N, N -diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1 H -benzimidazol-1- yl)ethan -1-amine); (109) Flunitazene (N, N -diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1 H -benzimidazol-1- yl)ethan -1-amine); (110) Metodesnitazene (N,6 N -diethyl-2-(2-(4-methoxybenzyl)-1 H -benzimidazol-1- yl)ethan -1-amine); (111) Protonitazene (N, N -diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1 H -benzimidazol-1- yl)ethan -1-amine); (112) Brorphine (1-(1-(1-(4- bromophenyl) ethyl )piperidin-4-yl)-1,3-dihydro-2 H - benzo [ d ]imidazol-2-one); (113) Zipeprol (1-methoxy-3-[4-(2-methoxy-2- phenylethyl)piperazin-1-yl]-1- phenylpropan-2-ol). B. OPIUM DERIVATIVES: Unless specifically exempt or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation. (1) Acetorphine ; (2) Acetyl dihydrocodeine ; (3) Benzyl morphine; (4) Codeine methylbromide ; (5) Codeine -N- Oxide; (6) Cyprenorphine ; (7) Desomorphine ; (8) Dehydro morphine; (9) Etorphine; (10) Heroin ; (11) Hydromorphinol ; (12) Methyldesorphine ; (13) Methyldihydromorphine ; (14) Morphine methylbromide ; (15) Morphine methylsulfonate ; (16) Morphine-N- Oxide; (17) Myrophine ; (18) Nicocodeine ; (19) Nicomorphine ; (20) Normorphine ; (21) Pholcodine; (22) Thebacon ; (23) Drotebanol; (24) 6AM; (6-acetylmorphine). C. STIMULANTS: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers. (1) Fenethylline; (2) N- ethylamphetamine ; (3) cis-4-methylaminorex; (4) N, N-dimethylamphetamine; (5) (BZP), 1-benzylpiperazine; N-benzylpiperazine; (6) (DCPP); 2,3-dichlorophenylpiperazine; (7) (DBZP); dibenzylpiperazine ; (8) (MBZP); methylbenzylpiperazine ; (9) ( mCPP ); meta- chlorophenylpiperazine ; (10) (MDBZP); methylenedioxybenzylpiperazine; (11) ( meOPP ); para- methoxyphenylpiperazine ; (12) ( pCPP ); para- chlorophenylpiperazine ; (13) ( pFPP ); para- fluorophenylpiperazine ; (14) (2-DPMP), desoxypipradrol ; 2-diphenylmethylpiperidine; (15) D2PM, diphenylprolinol ; diphenyl-2-pyrrolidinemethanol; (16) HDMP-28; methylnaphthidate ; (17) Nocaine , (+)-CPCA; 3α-carbomethoxy-4β-(4-chlorophenyl)-N- methylpiperidine ; (18) BTQ or butyltolylquinuclidine ; (2-Butyl-3-(p-tolyl)quinuclidine; (19) Methiopropamine ; (N-methyl-1- (thiophen-2-yl)propan-2-amine); (20) Mesocarb ; (N-phenyl-N′ -(3-(1-phenylpropan-2-yl)-1,2,3- oxadiazol-3-ium-5-yl) carbamimidate ); (21) Amineptine (7- [(10,11-dihydro-5H-dibenzo[ a,d ]cyclohepten-5- yl )amino] heptanoic acid ); (22) 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4- methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5- (4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine). D. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: (1) Mecloqualone; (2) Methaqualone; (3) Benzodiazepines; (a) Bromazepam; (b) Camazepam; (c) Cloxazolam; (d) Delorazepam; (e) Ethylloflazepate; (f) Fudiazepam; (g) Flunitrazepam; (h) Haloxazolam; (i) Ketazolam; (j) Loprazolam; (k) Lormetazepam; (l) Medazepam; (m) Nimetazepam; (n) Nitrazepam; (o) Nordiazepam; (p) Oxazolam; (q) Phenazepam (r) Pinazepam; (s) Tetrazepam; (t) Flubromazepam; (u) Diclazepam ; (v) Etizolam ; (w) Flualprazolam ; (x) Clonazolam ; (y) Flubromazolam ; (z) Bromazolam (4) Gamma hydroxybutyric acid and any chemical compound that is metabolically converted to GHB; (5) G amma butyrolactone and any chemical compound that is metabolically converted to GHB; (6) 1-4 butane diol and any chemical compound that is metabolically converted to GHB (7) GHV or 4-methyl-GHB; γ- hydroxyvaleric acid; (8) GVL; γ- valerolactone ; (9) MMQ; methylmethaqualone; (10) MBQ; mebroqualone. E. HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section only, the term “isomers” includes the optical, positional, and geometric isomers). (1) 3,4 -methylenedioxy amphetamine; (2) 5 - methoxy - 3,4-methylenedioxy amphetamine; (3) 3,4,5 -trimethoxy amphetamine; (4) Bufotenine; (5) DET; ( Diethyltryptamine ); (6) DMT; (Dimethyltryptamine); (7) DOM or STP; (4-methyl-2,5-dimethoxy amphetamine); (8) Lysergic acid amide; (9) Lysergic acid diethylamide ; (10) Mescaline; (11) Peyote; (12) N-ethyl-3-piperidyl benzilate ; (13) N-methyl-3-piperidyl benzilate ; (14) Psilocybin ; (15) Psilocyn ; (16) Parahexyl ( synthetic analog of delta‑9‑tetra­hydrocannabinol ); (17) 2, 5 - dimethoxyamphetamine ; 2, 5-DMA; (18) 4-bromo-2, 5-dimethoxy- amphetamine; 2, 5-DMA; (19) PMA; 4-methoxyamphetamine; (20) PCE; (Ethylamine N-ethyl-1-phenylcyclohexylamine); (21) Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine ( PCPy ), (PHP) analog of the drug phencyclidine; (22) Thiophene (analog of phencyclidine) TCP or TPCP; (23) Alpha- ethyltryptamine ; (24) 2, 5-dimethoxy-4-ethylamphet-amine; (25) Ibogaine; (26) 2C-T-7; (2,5-dimethoxy-4-(n)- propylthiophenethylamine ); (27) AMT; (Alpha-methyltryptamine); (28) 5-MeO-DIPT; (5-methoxy-N,N-diisopropyltryptamine); (29) 25B-NBOMe; (2-(4-bromo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine ); (30) 25C-NBOMe; (2-(4-chloro-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine); (31) 25I-NBOMe; (2-(4-iodo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine ). (32) Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following synthetic cannabinoids which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding activity. Substances include but are not limited to: (a) CP 55,244 ((hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl] 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol); (b ) CP 55,940 (5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol); (c) JWH-081 (1-pentyl-3-[1-(4-methoxynaphthoy)]indole); (d ) JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole); (e) JWH-133 3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H dibenzo[b,d]pyran; (f ) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole); (g ) JWH 210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl) methanone ; (h ) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole); ( i ) AM-1221 (1-(N-methylpiperdin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole; (j ) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole); (k ) RCS-4 or SR-19 (1-pentyl-3-[(4-methoxy)-benzoyl]indole); (l ) RCS-8 or SR-18 (1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole); (m ) JWH-210 (1-pentyl-3-(4-ethylnaphthoyl)indole); (n ) WIN-49,098 (Pravadoline) (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone; (o ) WIN-55,212-2 (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin6- yl )-1-naphthalenylmethanone); (p) any of the following synthetic cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation; ( i ) naphthoylindoles : any compound containing a 3-(1- naphthoyl ) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398 and AM-2201; (ii) naphthylmethylindoles : any compound containing a1Hindol- 3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-175, JWH-184, and JWH-199; (iii) naphthoylpyrroles : any compound containing a 3-(1- naphthoyl ) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-307; (iv) naphthylmethylindenes : any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-176; (v) phenylacetylindoles : any compound containing a 3- phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8; (vi) cyclohexylphenols : any compound containing a 2-(3- hydroxycyclohexyl ) phenol structure with substitution at the 5- position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol (CP 47,497 C8 homologue), CP 47,497 and CP 55,490; (vii) benzoylindoles : any compound containing a 3-(benzoyl) [ 5 ] OTS-3833.4 indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4- morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241 ; (q) UR-144 1-(pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl) methanone ; (r) XLR11 1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone; (s) AKB48 N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide; (t) QUPIC; Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate; (u) 5-fluoro-PB 22; 5F-PB22; Quinolin-8-yl 1-(5-fluropentyl-1H-indole-3-carboxylate; (v) AB- FUBINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-flurobenzyl)-1H-indazole-3-carboxamide; (w) ADB-PINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamine; (x) AB-CHMINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; (y) AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide; (z) THJ-2201; [1-(5-fluropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone ; (aa) FDU-PB-22 IUPAC: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3 carboxylate; ( bb ) 5-fluoro ABICA: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; (cc) FUB-144 or FUB-UR-144; [1-(4-fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; (dd) MN-18; N-(1-Naphthyl)-1-pentyl-1H-indazole-3-carboxamide; (ee) FUB-PB-22; Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate; (ff) ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide); (gg) AMB-FUBINACA or FUB-AMB ( methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate); (hh) 5-fluoro-AMB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester); (ii) 5-fluoro-ADB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine, methyl ester); (jj) Bk-DMBDB or dibutylone; 1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-one; (kk) MMB-FUBINACA; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate; (ll) MDMB-CHMICA; methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate; (mm) NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; (nn) 5-Fluoro-AKB48 or 5F-APINACA; N-((3s,5s,7s)-adamanta-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; (oo) 5-Fluoro-ADB; Methyl(S)-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate; (pp) 5-Fluoro-AMB; N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine,methyl ester; (qq) MAB-CHMINACA; N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cycohexylmethyl)-1H-indazole-3-carboxamide; (rr) SDB-006; N-benxyl-1-pentyl-1H-indole-3-carboxamide; (ss) Cumyl-PINACA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide; (tt) Cumyl-PICA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide ; (uu) 5F-CUMYL-PINACA; SGT-25; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2- yl)-1H-indazole-3-carboxamide; (vv) 5F-EDMB-PINACA; Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)- 3,3-dimethylbutanoate; (ww) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [5F-ADB; 5F-MDMB-PINACA]; (xx) N -(Adamantan-1-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide (FUB-AKB48; FUB-APINACA; AKB48 N -(4-fluorobenzyl)); (yy) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide (4-CN-CUMYL-BUTINACA, 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA, CUMYL-4CN-BINACA, or SGT-78); (zz) methyl 2-(1-(cyclohexylmethyl)-1 H-indole-3-carboxamido)-3-methylbutanoate (MMB-CHMICA or AMB-CHMICA); (aaa) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3- carboxamide (5F-CUMYL-P7AICA) (33) Substances determined by the board to have the pharmacological effect of the substance, the risk to the public health by abuse of the substance and the potential of the substance to produce psychic or physiological dependence liability is similar to the substances described in Paragraph (1) or (2) of 30-31-23C NMSA 1978. Substances include but are not limited to: (a) Salvia divinorum ; (b) Salvinorin A (methyl (2 S ,4a R ,6a R ,7 R ,9 S ,10a S ,10b R )-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2 H -benzo[f]isochromene-7-carboxylate); (34) (4-MEC); 4-methyl-ethylcathinone; (35) (4-EMC); 4-ethyl-methcathinone; (36) Ethcathinone ; 2-ethylamino-1-phenyl-propan-1-one; (37) Ethylone ; 3’,4’-methylenedioxyethcathinone; (38) Bk-MBDB, butylone; beta-keto-N-methyl-3,4-benzodioxyolybutanamine; (39) (NRG-1), naphyrone ; naphthylpyrovalerone ; (40) Metamfepramone; N,N-dimethylcathinone; (41) Alpha-PPP; alpha-pyrrolidinopropiophenone; (42) (α-PBP); alpha- pyrrolidinobutiophenone ; (43) (MOPPP); 4’-methoxy-alpha-pyrrolidinopropiophenone; (44) (MαPPP); 4’-methyl-α- pyrrolidinopropiophenone ; (45) (MDPPP); 3’,4’-methylenedioxy-alpha-pyrrolidinopropiophenone; (46) (MDPBP); 3’,4’-methylenedioxy-alpha-pyrrolidinobutiophenone; (47) (MPBP); 4’-methyl-α- pyrrolidinobutiophenone ; (48) Alpha-PVP; alpha-pyrrolidinovalerophenone; (49) (MDAI); 5,6-methylenedioxy-2-aminoindane; (50) Buphedrone ; alpha-methylamino-butyrophenone; (51) Eutylone ; beta-keto- ethylbenzodioxolylbutanamine ; (52) beta-keto- ethylbenzodioxolylpentanamine ; (53) beta-keto- methylbenzodioxolylpentanamine ( pentylone ); (54) 4-Bromo-2,5-dimethoxyphenethylamine (2c-B, Nexus); (55) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alphamethyl-3,4(methylenedioxy)-phenethylamine, and N-hydroxy MDA; (56) 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-[2-( dimethylamino )ethyl]indole; 5-MeO-DMT; (57) Mephedrone; 4-methylmethcathinone; (58) (MDPV); 3,4-methylenedioxypyrovalerone; (59) (2C-E); 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine ; (60) (2C-D); 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine ; (61) (2C-T-2); 2-[4-( Ethylthio )-2,5-dimethoxyphenyl] ethanamine ; (62) (2C-T4); 2-[4-( Isopropylthio )-2,5-dimethoxyphenyl] ethanamine ; (63) (2C-H); 2-(2,5-Dimethoxyphenyl) ethanamine ; (64) (2C-N); 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine ; (65) (2C-P); 2-(2,5-Dimethoxy-4-(n)- propylphenyl ) ethanamine ; (66) Methylone; 3,4-Methylenedioxy-N-methylcathinone; (67) Aminorex (2-amino-5-phenyl-2-oxazoline); (68) Pentedrone ; (69) 4-FMC or flephedrone ; 4-fluro-N-methylcathinone; (70) (3-FMC); 3-fluro-N-methylcathinone; (71) (3-MMC); 3-methylmethcathinone; (72) (3,4 DMMC); 3,4-Dimethylmethcathinone; (73) (3-MEC); 3-Methyl-N-ethylcathinone; (74) 4-methylbuphedrone or 4-MeBP; 2-methylamino-1-(4-methylphenyl)butan-1-one (75) (4 MTA); 4-methylthioamphetamine; (76) (5-Me MDA); 5-methyl-3,4-methylenedioxyamphetamine; (77) (6-APB); 6-benzofuran; (78) (PMA); 4-methoxyamphetamine; (79) (2C-B); 2,5-dimethoxy-4-bromophenethylamine; (80) (2C-C); 2,5-dimethoxy-4-chlorophenethylamine; (81) (2C-D); 4-methyl-2,5-dimethoxyphenethylamine; (82) (2C-E, aquarust , cindy ); 2,5-dimethoxy-4-ethylphenethylamine; (83) (2C-G); 3,4-dimethyl-2,5-dimethoxyphenethylamine; (84) (2C-I); 2,5-dimethoxy-4-iodophenethylamine; (85) (2C-T21); 2-[2,5-dimethoxy-4-(2-fluoroethylthio)phenyl] ethanamine ; (86) (2C-B-FLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4- yl) ethanamine ; (87) Bromo- DragonFLY or 3C-Bromo-Dragonfly or DOB- Dragonfly ; 1-(4-Bromofuro[2,3-f][1]benzofuran-8- yl)propan -2-amine; (88) (DOB); 2,5-Dimethoxy-4-bromoamphetamine; (89) (DOC); 2,5-Dimethoxy-4-chloroamphetamine; (90) (DOM); 2,5-Dimethoxy-4-methylamphetamine; (91) (TMA2); 2,4,5-trimethoxyamphetamine; (92) (TMA6); 2,4,6-trimethoxyamphetamine; (93) (MDAT); 6,7-methylenedioxy-2-aminotetralin; (94) (4-acetoxy DiPT , ipracetin ); 4-acetoxy-N,N-diisopropyltryptamine; (95) (4-acetoxy DMT, psilacetin ;) O- Acetylpsilocin ; (96) 4-HO MET, metocin ; 4-hydroxy-N-methyl-N-ethyltryptamine; (97) 4-HO MiPT , hats ; 4-hydroxy-N-methyl-N-isopropyltryptamine; (98) 5-MeO-aMT, Alpha-O; 5-methoxy- α - methyltryptamine ; (99) (5-MeO-MiPT); N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine; (100) (DiPT); N,N-diisopropyltryptamine; (101) (DPT); dipropyltryptamine; (102) (5-MeO-DALT); N,N -diallyl-5-methoxytryptamine; (103) (3-MeO PCP); 3-methoxyphencyclidine; (104) (4-MeO PCP); 4-methoxyphencyclidine; (105) (MK-801); dizocilpine; (106) (PCE, perchloroethylene, perchloroethene ), Perc; tetrachloroethylene; (107) (PCE, perchloroethylene, perchloroethene ), Perc; tetrachloroethylene; (108) ( PCPr ); phencyclamine , N-(1-phenylcyclohexyl) propanamine ; (109) (Tenocyclidine); 1-(1-(2-thienyl)cyclohexyl)piperidine (110) (3-MeO PCE); 3-methoxyeticyclidine, N-ethyl-1-(3-methoxyphenyl) cyclohexanamine ; (111) (ETH-LAD); 6-ethyl-6-nor-lysergic acid diethylamide; (112 (AL-LAD); 6-allyl-6-nor-LSD; (113) (PRO-LAD); 10-didehydroergoline-8-carboxamide; (114) ((1-(1,3-benzodioxol-5-yl)-2-( ethylamino )pentan-1-one, N- ethylpentylone ); (115) (MPHP), 4´-methyl-alpha-pyrrolidinohexiophenone; (116) 4'-chloro-alpha-pyrrolidinovalerophenone (4-chloro-α-PVP; 4'-chloro-α- pyrrolidinopentiophenone ); (117) 4-methyl-alpha-ethylaminopentiophenone (4-MEAP; 2-( ethylamino )-1-(4-methylphenyl)pentan-1-one); (118) Alpha- pyrrolidinoheptaphenone (PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one); (119) Alpha- pyrrolidinohexanophenone (α-PHP; α- pyrrolidinohexanophenone ; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); (120) N- ethylhexedrone (α- ethylaminohexanophenone ; 2-( ethylamino )-1- phenylhexan-1-one); (121) Methoxetamine; 2-( ethylamino )-2-(3-methoxyphenyl)cyclohexan-1-one; 2-(3-methoxyphenyl)-2-(N- ethylamino )cyclohexanone; MXE). F. Any material, compound, mixture or preparation which contains any quantity of the following substances. (1) 3, 4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts and salts of isomers; (2) (MPPP); 1-methyl-4-phenyl-4-proprionoxypiperidine its optical isomers, salts, and salts of isomers; (3) 1-(-2-phenylethyl)-4-phenyl-4-acetoxy piperidine (PEPAP), its optical isomers, salts and salts of isomers; (4) Cathinone; (5) Methcathinone; (6) Tianeptene ; (7) Para - Methoxymethamphetamine (PMMA) [16.19.20.65 NMAC - Rp 16.19.20.65 NMAC, 6/26/2018; A, 12/17/2019; A, 9/14/2021 ;

Instrument

20.10.2 NMAC (eff. 2026-01-28)

Source

https://www.env.nm.gov/cannabis-hemp/wp-content/uploads/sites/34/2026/01/Hemp-Final-Rule-Presentation-12.30.25.pdf

Retrieved

2026-10-07

Fingerprint

bb8bdb86e18c5c9e

[NMED final rule presentation, 20.10.2 NMAC:] [Hemp finished product means] "a product intended for retail sale to consumers for human consumption, cosmetics, or inhalation that contains hemp or hemp extract". [Total THC remains 0.30%. Except tinctures, broad spectrum products, vapes and cosmetics, a product may have] "No more than 2.0 mg / serving Total THC" [and] "No more than 20 mg / package." [Hemp Retail Manufacturer:] "an operation that produces or repackages hemp finished products and provides them directly to consumers." [Effective Jan. 28, 2026; 60-day items due Mar. 28, 2026.] [Bracketed spans summarized; full rule PDF at env.nm.gov not separately parsed.]

Instrument

20.10.2.7 NMAC (Definitions) and 20.10.2.11 NMAC (Hemp Facility Requirements) - NMED 2025 Emergency Rule

Source

https://www.env.nm.gov/cannabis-hemp/hemp-emergency-rule/

Retrieved

2026-07-02

Fingerprint

6101daef638c61b1

20.10.2.7 DEFINITIONS (emergency-amended definitions):

WW. "Semi-synthetic cannabinoid" means a substance that is created by a chemical reaction that converts one cannabinoid extracted from a Cannabis sativa L. directly into a different cannabinoid. Semi-synthetic cannabinoid does not include cannabinoids produced via decarboxylation of naturally occurring acidic forms of cannabinoids, such as Tetrahydrocannabinolic acid into the corresponding neutral cannabinoid, such as THC, through the use of heat or light, without the use of chemical reagents or catalysts, and that results in no other chemical change.

YY. "Synthetic cannabinoid" means a cannabinoid-like compound that was produced by using chemical synthesis, chemical modification, or chemical conversion. Synthetic cannabinoid does not include:
(1) A compound produced through the decarboxylation of naturally occurring cannabinoids from their acidic forms; or,
(2) A semi-synthetic cannabinoid.

ZZ. "THC" means delta-9 tetrahydrocannabinol (CAS number 1972-08-3) as measured using a post-decarboxylation method and based on percentage dry weight.

20.10.2.11 HEMP FACILITY REQUIREMENTS (emergency-amended subsections):

K. Except as provided in Subsections L and M of this section, when conducting activities authorized under the Act or this Part, a hemp facility shall not receive, possess, manufacture, offer, advertise, market, or sell semi-synthetic cannabinoids or synthetic cannabinoids or products containing semi-synthetic cannabinoids or synthetic cannabinoids.

L. Except as provided in Subsection M of this section, A hemp facility may receive and use as an ingredient in hemp finished products semi-synthetic cannabinoids or synthetic cannabinoids identified in Paragraphs (1) through (9) of this subsection, provided that before use in manufacturing, laboratory analysis completed by an approved analytical laboratory of the semi-synthetic cannabinoid or synthetic cannabinoid demonstrate the cannabinoid has a purity of greater than or equal to 98 percent. Semi-synthetic cannabinoids or synthetic cannabinoids meeting the purity requirements of this Subsection that may be received and used as an ingredient in hemp finished products are:
(1) Delta-9 tetrahydrocannabivarin tetrahydrocannabivarin (THCV);
(2) Cannabichromene (CBC);
(3) Cannabicitran (CBT);
(4) Cannabicyclol (CBL);
(5) Cannabielsoin (CBE);
(6) Cannabigerol (CBG);
(7) Cannabidivarin (CBDV);
(8) Cannabidiol (CBD); and
(9) Cannabinol (CBN).

M. Subsections L and M of this section are effective beginning September 15, 2025.

Instrument

statute

Source

https://law.justia.com/codes/new-mexico/chapter-30/article-31/section-30-31-6/

Retrieved

2026-06-19

Fingerprint

edae7dd1858c5776

**§ 30-31-6(C) (named tryptamines in the closed list)** — "(5) diethyltryptamine; (6) dimethyltryptamine; … (14) psilocybin …; (15) psilocin …"
— NMSA § 30-31-6(C), https://law.justia.com/codes/new-mexico/chapter-30/article-31/section-30-31-6/ (MIRROR: Justia). 4-HO-MET does not appear, and no 4-hydroxytryptamine structural class exists in the section.
**§ 30-31-2(U) (controlled substance analog)** — "'controlled substance analog' means a substance other than a controlled substance that has a chemical structure substantially similar to that of a controlled substance in Schedule I, II, III, IV or V or that was specifically designed to produce effects substantially similar to that of controlled substances in Schedule I, II, III, IV or V. Examples of chemical classes in which controlled substance analogs are found: (1) include: (a) phenethylamines; … (f) substituted indoles; and (g) arylcycloalkylamines …"
— NMSA § 30-31-2(U), https://law.justia.com/codes/new-mexico/chapter-30/article-31/section-30-31-2/ (MIRROR: Justia).

Instrument

Definitions (semi-synthetic/synthetic cannabinoid); Hemp Manufacturers and Retailers -- prohibition on semi-synthetic/synthetic cannabinoids

Source

https://www.nmlegis.gov/Sessions/25%20Regular/bills/house/HB0346.HTML

Retrieved

2026-07-19

Fingerprint

75deb47f9f20ac24

76-24-4. DEFINITIONS.--As used in the Hemp Manufacturing Act: E. "hemp" means the plant Cannabis sativa L. and any part of that plant, including seeds and all derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers, whether growing or not, with a THC concentration of not more than three-tenths percent or a concentration allowed by federal law, whichever is greater, based on dry weight; F. "hemp extract" means oil and extracts derived from hemp, containing THC in any concentration, including cannabidiol, cannabidiolic acid and other identified and non-identified compounds; G. "hemp finished product" means a product for human ingestion or inhalation that contains hemp or hemp extracts and is intended to be provided to consumers; J. "hemp retailer" means a person that provides hemp finished products directly to consumers; M. "semi-synthetic cannabinoid" means a substance that is created by a chemical reaction that converts one cannabinoid extracted from Cannabis sativa L. directly into a different cannabinoid; provided that "semi-synthetic cannabinoid" does not include a cannabinoid produced via decarboxylation of naturally occurring acidic forms of cannabinoids, such as tetrahydrocannabinolic acid, into the corresponding neutral cannabinoid, such as THC, through the use of heat or light without the use of chemical reagents or catalysts and that results in no other chemical change; N. "synthetic cannabinoid" means a cannabinoid-like compound that was produced by using chemical synthesis, chemical modification or chemical conversion; provided that "synthetic cannabinoid" does not include (1) a compound produced through the decarboxylation of naturally occurring cannabinoids from their acidic forms; or (2) a semi-synthetic cannabinoid; and O. "THC" means delta-9-tetrahydrocannabinol as measured using a post-decarboxylation method and based on percentage dry weight. 76-24-8. HEMP MANUFACTURERS--PERMITS--RULES--REQUIREMENTS.--A. The department of environment shall issue permits pursuant to rules adopted in accordance with Subsection C of this section to extract, process or engage in other manufacturing activities regarding hemp, including manufacturing hemp extract and hemp finished products. B. Except as specified in Subsection I of this section, a person shall not extract, process or engage in other manufacturing activities regarding hemp, including manufacturing hemp extract and hemp finished products without a permit issued by the department of environment or a license issued pursuant to Subsection C of Section 76-24-10 NMSA 1978. J. Hemp finished products manufactured pursuant to this section shall not have a THC concentration of more than three-tenths percent or a concentration allowed by federal law, whichever is greater. K. A hemp manufacturer shall not receive, possess, offer, advertise, market or sell products containing semi-synthetic cannabinoids or synthetic cannabinoids. HEMP RETAILERS--RULES--REQUIREMENTS.-- A. Beginning July 1, 2025, the environmental improvement board shall adopt rules for hemp retailers that include: (1) requirements for hemp products received, possessed, offered, advertised, marketed or sold; (2) labeling requirements; (3) facility registration; (4) purchasing, storage and recordkeeping requirements; (5) inspection and enforcement by the department of environment; and (6) procedures for appeal. C. Hemp retailers shall not receive, possess, offer, advertise, market or sell hemp finished products that have a THC concentration of more than three-tenths percent or a concentration allowed by federal law, whichever is greater, or hemp finished products containing semi-synthetic cannabinoids or synthetic cannabinoids.

Instrument

Hemp Manufacturing Act - Definitions

Source

https://law.justia.com/codes/new-mexico/chapter-76/article-24/section-76-24-4/

Retrieved

2026-07-02

Fingerprint

a9bdb246e8f52d61

As used in the Hemp Manufacturing Act:

A. "board" means the board of regents of New Mexico state university;

B. "breeder" means a person who conducts research to develop new hemp varieties;

C. "Cannabis sativa L." means the plant Cannabis sativa L. and any part of the plant, whether growing or not;

D. "hemp" means the plant Cannabis sativa L. and any part of that plant, including seeds and all derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers, whether growing or not, with a THC concentration of not more than three-tenths percent on a dry weight basis;

E. "hemp-derived material" means any material containing THC in any concentration derived from Cannabis sativa L. through any activity authorized pursuant to the Hemp Manufacturing Act;

F. "hemp extract" means oil derived from hemp, including cannabidiol, cannabidiolic acid and other identified and non-identified compounds;

G. "hemp finished product" means a hemp product that is intended for retail sale and containing hemp or hemp extracts that includes food, food additives and herbs for human use, including consumption, that has a THC content of not more than three-tenths percent;

H. "hemp manufacturer" means a person that extracts, processes or engages in other manufacturing activities regarding hemp, including manufacturing intermediate hemp-derived products and hemp finished products;

I. "hemp producer" means a person that cultivates and harvests hemp and includes a person that cultivates hemp plants for transfer to other hemp producers;

J. "intermediate hemp-derived product" means oil and extracts, including cannabidiol, cannabidiolic acid and other identified and non-identified compounds derived from hemp;

K. "manifest" means a form used for identifying the quantity, composition, origin, routing and destination of hemp-derived materials during transportation; and

L. "THC" means delta-9-tetrahydrocannabinol as measured using a post-decarboxylation method and based on percentage dry weight.

Instrument

Controlled Substances Act - Definitions - controlled substance analog

Source

https://law.justia.com/codes/new-mexico/chapter-30/article-31/section-30-31-2/

Retrieved

2026-07-20

Fingerprint

91a1298334575cee

U. "controlled substance analog" means a substance other than a controlled substance that has a chemical structure substantially similar to that of a controlled substance in Schedule I, II, III, IV or V or that was specifically designed to produce effects substantially similar to that of controlled substances in Schedule I, II, III, IV or V. Examples of chemical classes in which controlled substance analogs are found: (1) include: (a) phenethylamines; (b) N-substituted piperidines; (c) morphinans; (d) ecgonines; (e) quinazolinones; (f) substituted indoles; and (g) arylcycloalkylamines; and (2) do not include those substances that are generally recognized as safe and effective within the meaning of the Federal Food, Drug, and Cosmetic Act or have been manufactured, distributed or possessed in conformance with the provisions of an approved new drug application or an exemption for investigational use within the meaning of Section 505 of the Federal Food, Drug, and Cosmetic Act;